tiprankstipranks
Advertisement

SIXL - ETF AI Analysis

Compare

Top Page

SIXL

ETC 6 Meridian Low Beta Equity ETF (SIXL)

Rating:70Neutral
Price Target:
SIXL, the ETC 6 Meridian Low Beta Equity ETF, has an overall rating that points to a generally solid but not flawless portfolio, with several strong holdings helping support its quality. Standout positions like PGNY and ELV boost the fund’s appeal through strong financial performance, positive outlooks, and supportive technical trends, while names such as DVA and VIRT introduce some drag due to profitability, stability, and leverage concerns. The main risk factor is exposure to companies with bearish or cautious technical signals and financial challenges, which could add volatility despite the fund’s low-beta focus.
Positive Factors
Broad Sector Diversification
The fund spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.
Generally Strong Top Holdings
Most of the largest positions have shown strong year-to-date performance, which has supported the ETF’s recent gains.
Defensive, Lower-Volatility Tilt
Heavy exposure to traditionally defensive areas like utilities, consumer defensive, health care, and real estate aligns with the fund’s low-beta strategy and may help smooth returns in choppy markets.
Negative Factors
Higher-Than-Average Expense Ratio
The fund’s fee is on the higher side for an ETF, which can gradually eat into long-term returns compared with lower-cost options.
Concentrated in U.S. Market
With almost all assets in U.S. stocks, the ETF offers little geographic diversification and remains highly tied to the U.S. economy and market conditions.
Some Lagging Individual Holdings
At least one of the top positions has shown weak year-to-date performance, which can drag on overall results if it does not improve.

SIXL vs. SPDR S&P 500 ETF (SPY)

SIXL Summary

The ETC 6 Meridian Low Beta Equity ETF (SIXL) is a U.S. stock fund that aims to give you broad market exposure while focusing on companies whose share prices tend to move less than the overall market. It doesn’t track a specific index, but it leans toward steadier areas like utilities, consumer defensive, financials, health care, and real estate. Well-known holdings include Verisign and Murphy USA. Someone might invest in SIXL to seek smoother, more stable growth and diversification across many sectors. A key risk is that it can still lose value and will go up and down with the stock market over time.
How much will it cost me?The ETC 6 Meridian Low Beta Equity ETF (Ticker: SIXL) has an expense ratio of 0.47%, meaning you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it is actively managed, focusing on selecting low beta stocks to reduce market volatility. This strategy requires more research and management compared to passively managed funds.
What would affect this ETF?The SIXL ETF, with its focus on low beta equities and strong exposure to sectors like Utilities, Consumer Defensive, and Health Care, could benefit from economic stability or increased demand for defensive stocks during market uncertainty. However, it may face challenges if interest rates rise, as sectors like Real Estate and Utilities are sensitive to borrowing costs, or if growth-oriented sectors like Technology underperform. Its U.S.-centric exposure also ties its performance closely to domestic economic conditions and regulatory changes.

SIXL Top 10 Holdings

SIXL’s story is less about flashy mega-caps and more about a steady cast of U.S. low-volatility names. Health care and financials quietly set the tone, with DaVita and Elevance Health rising and helping anchor returns, even if DaVita’s momentum looks a bit choppy. On the financial side, Virtu Financial is climbing but still wrestling with leverage, while United Fire Group adds a more stable, dividend-flavored note. TG Therapeutics and Protagonist Therapeutics bring a punchier biotech edge, but their mixed signals can make the ride bumpier than the fund’s low-beta label might suggest.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
TG Therapeutics0.75%$1.48M$8.16B54.17%
65
Neutral
Progyny0.70%$1.38M$2.37B44.20%
79
Outperform
CoreCivic0.69%$1.36M$3.07B32.82%
73
Outperform
DaVita0.64%$1.26M$15.08B62.94%
59
Neutral
John Wiley Sons Cl A0.62%$1.22M$2.68B22.57%
69
Neutral
The Chefs' Warehouse0.61%$1.22M$3.90B56.50%
72
Outperform
Virtu Financial0.61%$1.21M$9.58B40.43%
64
Neutral
Elevance Health0.59%$1.17M$90.75B17.67%
76
Outperform
Protagonist Therapeutics0.58%$1.16M$8.46B163.68%
68
Neutral
United Fire Group0.58%$1.15M$1.38B91.13%
71
Outperform

SIXL Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
38.36
Positive
100DMA
38.32
Positive
200DMA
37.43
Positive
Market Momentum
MACD
0.45
Negative
RSI
61.09
Neutral
STOCH
64.21
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SIXL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.96, equal to the 50-day MA of 38.36, and equal to the 200-day MA of 37.43, indicating a bullish trend. The MACD of 0.45 indicates Negative momentum. The RSI at 61.09 is Neutral, neither overbought nor oversold. The STOCH value of 64.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SIXL.

SIXL Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$195.74M0.46%
70
Neutral
$940.18M0.59%
69
Neutral
$876.23M1.30%
68
Neutral
$799.05M0.45%
74
Outperform
$773.59M0.22%
63
Neutral
$706.70M0.18%
71
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SIXL
ETC 6 Meridian Low Beta Equity ETF
39.70
3.99
11.17%
SYLD
Cambria Shareholder Yield ETF
ULTY
YieldMax Ultra Option Income Strategy ETF
BGDV
Bahl & Gaynor Dividend ETF
AVTM
Avantis Total Equity Markets ETF
VFMF
Vanguard U.S. Multifactor ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement